Flynn says provisional UK drug-pricing decision is ‘fundamentally flawed’
Drug company Flynn has heavily criticized the UK competition regulator’s provisional finding that it and Pfizer broke competition law by charging unfairly high prices for phenytoin sodium capsules. The UK-based company...To view the full article, register now.
Already a subscriber? Click here to view full article